If you are on the hunt for some of the best ASX shares to buy this month, then it could pay to listen to analysts at Bell Potter.
They have revealed a number of shares that they believe are best buys right now and could offer good returns in 2026. Let's see what the broker is bullish on in January:
Region Group (ASX: RGN)
The first ASX share that could be a best buy is Region Group. It offers a defensive way to gain exposure to Australian retail property. The company owns a portfolio of neighbourhood and sub-regional shopping centres anchored by supermarkets and essential services. This positioning helps stabilise rental income, as demand for food, healthcare, and everyday services tends to hold up even when discretionary spending softens.
Bell Potter sees value in Region Group's focus on convenience-based retail, which benefits from high foot traffic and resilient tenant demand. With inflation-linked rental growth and improving operating conditions across parts of the retail property sector, the broker believes the company is well placed to deliver steady income and long-term value for investors. It said:
Whilst the immediate catalyst is valuation uplift, we also see a strong case for medium-term rental growth (c.15% under rented vs. benchmark; 9.7% specialty occupancy cost ratio is low vs historical levels/peers), adding to our longer-term conviction in the stock.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another ASX share that Bell Potter is bullish on is Telix Pharmaceuticals. It specialises in radiopharmaceuticals used in the diagnosis and treatment of cancer, which is an area of medicine that continues to attract strong interest and investment globally.
Its flagship products and development pipeline position Telix at the heart of medical innovation and increasing demand for more targeted cancer therapies.
Bell Potter is positive on Telix's commercial momentum and longer-term growth outlook. As adoption of its products expands and new therapies progress through development, the broker believes Telix has the potential to deliver strong earnings growth over time. Especially with potential product approvals on the horizon. It said:
We are confident regarding the approval in CY 2026 of Zircaix following resubmission of the Biological License Application (BLA). The FDA rejected the original BLA due to CMC (chemistry manufacturing & control) matters at Telix's manufacturing partner. There were no matters related to safety or efficacy.
We expect the market for Zircaix once approved will be in excess of US$500m. The product has been included in guidelines for disease management in the US and Europe and continues to be available in the US under the expanded access program. Elsewhere, sales of Iluuccix/ Gozellix in the PSMA franchise continue to grow and were recently boosted by the refresh on the pass through pricing.
